Building on these encouraging results with α-emitters in treatment of hematological malignancies and due to the high expression of CD38 in malignant plasma cells we evaluated therapeutic efficacy of 213Bi-anti-CD38 radioimmunoconjugates in multiple myeloma both in vitro and in vivo. Here, CD38 is linked to AL amyloidosis.